What is Liquidia Corporation's market cap?

Liquidia Corporation (LQDA) has a market capitalization of $7.5B and trades on NASDAQ.

What is Liquidia Corporation's revenue and profitability?

Liquidia Corporation generated $288.1M in trailing twelve-month revenue with a net loss of $30.6M, representing a net margin of -176.2%. Gross margin stands at 58.1%, with free cash flow of -$32.1M. These figures are based on the Q1 2026 filing.

Who are Liquidia Corporation's competitors?

Liquidia Corporation's key competitors include United Therapeutics Corporation, MannKind Corporation, Theravance Biopharma, Inc., and others. These companies compete in similar markets and product categories.

Who does Liquidia Corporation partner with?

Liquidia Corporation's notable partners include Sandoz Inc., Pharmosa Biopharm Inc., United Therapeutics Corporation.

What subsidiaries does Liquidia Corporation have?

Liquidia Corporation's subsidiaries include Liquidia Technologies, Inc., Liquidia PAH, LLC.

Where is Liquidia Corporation headquartered?

Liquidia Corporation is headquartered in United States of America and employs approximately 145 people. It has been publicly traded since 2018.

Liquidia Corporation

LQDA

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing innovative therapies for challenging respiratory and vascular diseases.

Market cap

$7.51B+360%

Revenue$288.1M+1,937%

Net income-$30.6M+76.1%

Free cash flow-$32.1M+67.4%

EPS (diluted)-$0.46+72.0%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 11, 2026

Revenue$132.9MBeat by $13.4M EPS$0.52Beat by $0.18

Read the full report

Next report

Aug 11, 2026 (In 1 week)

Revenue estimate$168.5M

EPS estimate$0.76

Financials

Q1 2026

Income statement

See full

Revenue$132.9M+4,158%

Operating income$61.5M+274%

Net income$52.9M+238%

EPS (diluted)$0.52+216%

Balance sheet

See full

Cash & equivalents$222.8M+31.2%

Total debt$7.0M+1.5%

Total equity$108.6M+118%

Total assets$401.5M+76.6%

Cash flow

See full

Operating cash flow$53.0M+273%

CapEx$2.8M+758%

Free cash flow$50.2M+262%

Valuation & ratios

Valuation

See full

Market cap$7.51B+360%

Enterprise value$7.29B+377%

P/S26.1×-61.6×

Returns & leverage

See full

Debt / equity0.1×-0.1×

Current ratio2.2×-0.7×

Segments

By segment

See full

Single Reportable$132.9M+4,158%

By product

See full

Service$3.0M-4.4%

Competitors

By market cap

United Therapeutics$26.3B+95.5%

LQD

Liquidia Corporation$7.5B+343%

Mirum Pharmaceuticals, Inc.$7.0B+173%

Mannkind$1.2B+1.4%

Theravance Biopharma$873.8M+58.0%

Zevra Therapeutics, Inc.$574.0M-2.9%

Rein Therapeutics Inc.$66.9M+114%

SCN

Scienture Holdings, Inc.$14.9M-43.4%

By revenue growth

LQD

Liquidia Corporation+1,937%

Zevra Therapeutics, Inc.+201%

Theravance Biopharma+68.2%

Mirum Pharmaceuticals, Inc.+50.2%

Mannkind+21.2%

United Therapeutics+5.9%

By net margin

Theravance Biopharma104.34%+194pp

Zevra Therapeutics, Inc.101.58%+328pp

United Therapeutics40.61%+0.2pp

Mannkind9.32%-7.8pp

Mirum Pharmaceuticals, Inc.-140.24%-120pp

LQD

Liquidia Corporation-176.24%+896pp

Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing innovative therapies for challenging respiratory and vascular diseases. The company leverages its proprietary PRINT technology to engineer precise, uniform drug particles designed to improve therapeutic profiles and patient delivery. Its primary focus is on treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Competitive position

Liquidia is a specialized player in the pulmonary hypertension market, competing through proprietary particle engineering technology and differentiated delivery mechanisms.

GeographiesUnited States, Global

Customer segmentsSpecialized Healthcare Providers, Respiratory Patients, Vascular Disease Patients

Business modelProduct-based, Licensing, Profit-sharing

SuppliersRaw material suppliers, Contract manufacturing organizations, Technology licensors

CustomersSpecialty pharmacies, Hospitals, Pulmonologists, Cardiologists

CountryUnited States of America

Listed2018

Employees145.0

CEORoger A. Jeffs

SectorHealthcare

IndustryBiotechnology

Websiteliquidia.com

FilingsSEC EDGAR

Ask your AI about Liquidia Corporation.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Liquidia Corporation's market cap?: Liquidia Corporation (LQDA) has a market capitalization of $7.5B and trades on NASDAQ.
What is Liquidia Corporation's revenue and profitability?: Liquidia Corporation generated $288.1M in trailing twelve-month revenue with a net loss of $30.6M, representing a net margin of -176.2%. Gross margin stands at 58.1%, with free cash flow of -$32.1M. These figures are based on the Q1 2026 filing.
Who are Liquidia Corporation's competitors?: Liquidia Corporation's key competitors include United Therapeutics Corporation, MannKind Corporation, Theravance Biopharma, Inc., and others. These companies compete in similar markets and product categories.
Who does Liquidia Corporation partner with?: Liquidia Corporation's notable partners include Sandoz Inc., Pharmosa Biopharm Inc., United Therapeutics Corporation.
What subsidiaries does Liquidia Corporation have?: Liquidia Corporation's subsidiaries include Liquidia Technologies, Inc., Liquidia PAH, LLC.
Where is Liquidia Corporation headquartered?: Liquidia Corporation is headquartered in United States of America and employs approximately 145 people. It has been publicly traded since 2018.